Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that nanostructured lipid carriers with melatonin improved hair density and decreased hair loss in patients with androgenic alopecia, suggesting a promising direction for future treatments.

This study suggests that down-regulation of vasculature-related genes in dermal papilla cells from balding scalps might contribute to the development of androgenetic alopecia.

This review describes how recent discoveries in genetic defects and alternative pathways in androgen biosynthesis are reshaping our understanding of male sexual differentiation, but it presents no new clinical findings.

This study found that trichodynia is common among patients with telogen effluvium and androgenetic alopecia, and it often coexists with psychological issues like depression and anxiety.

In this study, depression was more common among women with androgenetic alopecia, while men showed higher levels of anxiety, aggressiveness, and a lack of adherence to treatment.

This review discusses the physiopathology of androgenetic alopecia and evaluates various traditional and emerging treatments, reporting no new clinical results but highlighting the need for enhanced treatment strategies.

This review discusses the molecular mechanisms of masculinization involving androgen signaling and their roles in male embryonic development and conditions like hypospadias and prostate cancer, and reports no clinical results.

This review discusses the association between androgen receptor gene polymorphism and PCOS, reporting mixed findings on whether shorter or longer CAG repeats are linked to the disorder; it provides no new results and calls for further studies.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study found that women with early-onset androgenetic alopecia had higher aldosterone levels and blood pressure, suggesting a possible link to the increased prevalence of hypertension in this group.

This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.

In a 24-week randomized trial, this study found that the RAMACAP laser helmet significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, although limitations included a small sample size and potential issues with the control used.

This review discusses the use of platelet-rich plasma as a treatment for androgenetic alopecia and highlights the need for standardized protocols, reporting no new clinical results.

This study found that low-level laser therapy may improve hair growth in patients with androgenetic alopecia, either as a standalone treatment or combined with minoxidil or finasteride, without reported adverse reactions.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This review discusses the etiology of polycystic ovary syndrome, emphasizing the role of genetic and environmental factors, and reports no new experimental findings.

In this study, germacrone from Curcuma aeruginosa showed anti-androgenic effects by inhibiting 5α-reductase, suggesting its potential as a lead compound for treating androgen-dependent disorders.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.

This study suggests that androgen receptor gene CAG repeat length may influence serum free testosterone levels in some PCOS patients, with longer repeats associated with higher testosterone concentrations.

This research suggests that testosterone-induced expression of TGF-beta1 and type I procollagen may lead to perifollicular fibrosis in androgenetic alopecia, with finasteride inhibiting this process as a possible mechanism for its effects.

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.

This study found that both 2% and 3% topical minoxidil were more effective than placebo in promoting hair growth for men with male pattern baldness over 12 months.

In this study, autologous non-activated platelet-rich plasma was associated with greater hair re-growth than autologous activated platelet-rich plasma over long-term follow-up.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

This study found that 5 mg/day oral finasteride was effective and safe for improving hair outcomes in normoandrogenic postmenopausal women with androgenetic alopecia over 18 months.

This chapter reviews recent findings on androgen receptor function, structure, and interactions, highlighting post-translational modifications and mutations related to prostate cancer, but reports no new experimental results.

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

This study found that the prevalence of personality disorders in individuals with androgenetic alopecia was significantly higher than in the general population, irrespective of gender.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study confirmed that a sulfotransferase enzyme test can effectively rule out 95.9% of nonresponders to 5% topical minoxidil for treating androgenetic alopecia.